RenovoRx (RNXT)

• Market cap: $50.5M
• 1 day: -2.61%
• 5 days: 16.03%
• 1 month: 20.75%
• 3 months: 27.26%
• 6 months: 16.16%
• Year to date: 34.1%
• 1 year: -6.67%
• 5 years: -84.57%
• 10 years: -84.57%
• Sector: Healthcare
• Industry: Biotechnology

About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Employees: 17